Schizophrenia and related psychotic disorders affect approximately 24 million people globally, with positive, negative, and cognitive symptom domains carrying distinct treatment challenges. Second-generation antipsychotics are the pharmacological foundation; long-acting injectable formulations improve adherence in relapse-prone patients. Muscarinic receptor agonists represent a mechanistically novel advance, with xanomeline-trospium receiving FDA approval in 2024.
DSM Future: Does Diagnostic Validity Still Matter?
The DSM's evolving diagnostic criteria raise questions about validity, impacting clinical practice and research in psychiatry.
Cannabis Psychosis Presents With Distinct Symptom Pattern
First-episode psychosis associated with cannabis exposure shows a distinct symptom profile compared to non-cannabis-associated psychosis.
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12